Sugi Predict

Sugi Predict / Compounds / SCHEMBL20116142

SCHEMBL20116142

SCHEMBL20116142

Cc1ccc(N2CC(C(=O)N3CCC(C(=O)O)CC3)CC2=O)cc1C

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.60
▸ TSHR P16473 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ RECQL P46063 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ MCL1 Q07820 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ CA12 O43570 2/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116446 0.88 KMT2A (0.57) POLBSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL30506338 0.88 KMT2A (0.57) POLBSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL20117008 0.88 KMT2A (0.50) POLBTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL20116457 0.86 POLB (0.78) POLBTSHRSMN1; SMN2KMT2ARECQL
SCHEMBL20116652 0.86 KMT2A (0.51) POLBTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL21609968 0.86 KMT2A (0.52) POLBTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL21609969 0.86 KMT2A (0.51) POLBTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL20116498 0.85 RAB9A (0.52) POLBTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL20676549 0.84 KMT2A (0.52) POLBTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL20116263 0.83 SMN1; SMN2 (0.65) POLBTSHRSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 — — CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 — — CN disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 POLB 3788/4885TSHR 4679/4885SMN1; SMN2 13/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 POLB 3788/4885TSHR 4679/4885SMN1; SMN2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.